Medical Significance and Treatments of Hypernatremia in Cirrhosis of the Liver

Albert Burak^*
*Correspondence: Albert Burak, Department of Chronic Disease Epidemiology, Medical University of Lodz, 92-213 Lodz, Poland, Email:

Keywords

Hyponatremia • Cirrhosis • Sodium intake • Urinalysis

Introduction

Cirrhosis is a late stage of scarring (fibrosis) of the liver caused by many forms of liver diseases and conditions, such as hepatitis and chronic alcoholism. The liver carries out several necessary functions, including detoxifying harmful substances in the body, cleaning the blood, and making vital nutrients. Cirrhosis can lead to a decline in liver function, impacting these vital processes. The progression of cirrhosis is marked by the development of fibrous tissue that replaces healthy liver tissue. This fibrosis impairs the liver's ability to function correctly. While it can occur due to various liver diseases and conditions, hyponatremia in cirrhosis is a critical aspect that requires special attention.

Literature Review

Hyponatremia is a condition characterized by a low concentration of sodium in the blood. Sodium is a crucial electrolyte that plays a vital role in regulating the body's fluid balance, maintaining blood pressure, and facilitating nerve and muscle function. Hyponatremia is often defined as a serum sodium level below 135 mEq/L. Hyponatremia is associated with a significant increase in mortality among cirrhotic patients. Studies have shown that hyponatremia in cirrhosis is an independent predictor of poor outcomes, with a higher risk of complications, hospitalization, and death. Low sodium levels can lead to a range of complications in cirrhotic patients, including hepatic encephalopathy (a decline in brain function due to liver disease), renal dysfunction, and an increased risk of bacterial infections.

Hyponatremia in cirrhosis can cause symptoms such as confusion, lethargy, muscle cramps, and nausea, negatively impacting a patient's overall quality of life [1]. Cirrhosis often leads to the accumulation of ascetic fluid in the abdominal cavity, known as ascites. This fluid shift can dilute the sodium concentration in the blood. Cirrhosis can impair the kidney's ability to excrete excess water and maintain sodium balance, leading to water retention and hyponatremia. The body's response to cirrhosis can activate neurohormonal systems, such as the renin-angiotensin-aldosterone system and the sympathetic nervous system. These systems can lead to sodium retention and contribute to hyponatremia.

Diuretics, which are often prescribed to manage ascites, can further exacerbate hyponatremia by promoting the excretion of sodium and water. Malnutrition is common in cirrhosis, and inadequate dietary sodium intake can contribute to low serum sodium levels. Early signs of hyponatremia can include confusion, altered mental status, headache and dizziness. Patients may experience muscle weakness and cramps due to altered nerve function. Gastrointestinal symptoms like nausea and vomiting can occur. The low sodium levels can lead to fluid retention, causing swelling in the extremities and abdomen. In severe cases, hyponatremia can lead to seizures, coma, and even death.

It is crucial for healthcare providers to be vigilant about monitoring sodium levels in cirrhotic patients and promptly addressing hyponatremia to prevent the progression of symptoms and complications. Healthcare providers assess the patient's medical history, symptoms, and clinical signs. A urinalysis may be conducted to assess the kidney's ability to excrete water appropriately. Further tests, such as liver function tests, are performed to determine the severity and underlying cause of cirrhosis. The underlying cause of hyponatremia in cirrhosis may also be investigated to guide treatment decisions. The management of hyponatremia in cirrhosis is multifaceted, aiming to correct the sodium imbalance while addressing the underlying liver disease. In mild cases of hyponatremia, limiting fluid intake can help raise serum sodium levels. Patients should adhere to strict fluid restrictions, typically around 1 to 1.5 litres per day [2].

In cases where hyponatremia is not severe, sodium supplementation in the form of oral sodium tablets or dietary sodium intake may be recommended. Adjusting the dosage of diuretics, such as spironolactone and furosemide, can help manage fluid retention and improve sodium levels. Vaptans are a class of medications that specifically target the vasopressin receptor, allowing the kidneys to excrete excess water. They can be used in more severe cases of hyponatremia in cirrhosis, but their use should be closely monitored due to potential side effects. Managing the underlying cause of cirrhosis is crucial to improve liver function and, indirectly, sodium balance. This may include addressing alcohol consumption, treating viral hepatitis, or providing supportive care. In advanced cases of cirrhosis, where liver function is severely compromised, a liver transplant may be the ultimate treatment option [3].

Discussion

Hyponatremia in cirrhosis is a critical clinical issue due to its far-reaching consequences on patient outcomes. While cirrhosis itself is a severe and progressive condition, the addition of hyponatremia complicates the management and prognosis. Here are some key points that underscore the clinical significance of hyponatremia in cirrhosis. Numerous studies have demonstrated that hyponatremia in cirrhotic patients significantly increases the risk of mortality. The reason behind this heightened risk is multifaceted. Hyponatremia affects multiple body systems and can lead to complications, which worsen the prognosis of cirrhosis.

Hyponatremia can exacerbate cirrhosis-related complications. For example, the risk of hepatic encephalopathy, a neuropsychiatric syndrome common in cirrhotic patients, is notably increased in those with low sodium levels. This can result in confusion, personality changes, and, in severe cases, coma. The kidneys play a crucial role in maintaining sodium balance in the body. However, in cirrhosis, the liver's impaired function can disrupt renal mechanisms responsible for fluid and electrolyte regulation [4]. As a result, hyponatremia often reflects underlying kidney dysfunction, which further complicates the clinical picture. Beyond the medical significance, hyponatremia in cirrhosis can significantly impact a patient's quality of life. The symptoms of hyponatremia, such as confusion, weakness, and nausea, can make daily living more challenging and less enjoyable.

Hyponatremia often necessitates hospitalization. The need for frequent monitoring and treatment, especially in severe cases, places a significant burden on healthcare resources and the patient. Understanding the underlying causes of hyponatremia in cirrhosis is essential for effective management. Several factors contribute to the development of hyponatremia in cirrhosis. Ascites, the accumulation of fluid in the abdominal cavity, is common in cirrhotic patients. This fluid shift can dilute the sodium concentration in the blood, contributing to hyponatremia. The progression of cirrhosis can impair the kidneys' ability to excrete excess water and maintain sodium balance. This renal dysfunction results in water retention and sodium loss, exacerbating hyponatremia.

The body's response to cirrhosis often activates neurohormonal systems, such as the renin-angiotensin-aldosterone system and the sympathetic nervous system. These systems can lead to sodium retention, further contributing to hyponatremia. Diuretics are frequently prescribed to manage ascites in cirrhotic patients. However, they can promote the excretion of sodium and water, increasing the risk of hyponatremia. Malnutrition is common in cirrhosis, and inadequate dietary sodium intake can contribute to low serum sodium levels. Accurate and timely diagnosis of hyponatremia in cirrhosis is crucial for initiating appropriate treatment and preventing complications [5]. The diagnosis typically involves the following steps. The patient's clinical history, symptoms, and physical examination are considered. Particular attention is paid to signs of hepatic encephalopathy, fluid retention and altered mental status.

A blood test is conducted to measure the serum sodium concentration. In cirrhotic patients, this level is often less than 130 mEq/L, indicating hyponatremia. Urinalysis can help determine the kidney's ability to excrete water properly, which is crucial in understanding the underlying cause of hyponatremia. Further tests, including liver function tests and imaging, may be performed to assess the severity of cirrhosis and its underlying cause. By accurately diagnosing hyponatremia in cirrhosis, healthcare providers can tailor their treatment strategies to the individual patient's condition.

The treatment of hyponatremia in cirrhosis aims to correct the sodium imbalance while addressing the underlying liver disease. The choice of treatment depends on the severity of hyponatremia and the specific clinical situation. Common treatment options include, in mild cases of hyponatremia, fluid restriction is often the first line of treatment. Patients are advised to limit their daily fluid intake to around 1 to 1.5 liters, which helps prevent further dilution of sodium in the bloodstream. For less severe cases, sodium supplementation may be recommended. This can be achieved through dietary sodium intake and oral sodium tablets. In patients with cirrhotic ascites, adjusting the dosage of diuretics may help manage fluid retention and improve sodium levels. Careful monitoring is necessary to avoid over diuresis. Strategies to prevent the development of hyponatremia in cirrhotic patients are also under investigation. This may include early identification of those at higher risk and proactive interventions [6].

Conclusion

Hyponatremia in cirrhosis is a multifaceted and clinically significant condition that affects both the prognosis and quality of life of cirrhotic patients. It is crucial for healthcare providers to be vigilant in monitoring sodium levels in these patients and addressing hyponatremia promptly. By understanding the underlying causes and tailoring treatment strategies, healthcare professionals can improve patient outcomes and ultimately provide better care and support to individuals living with cirrhosis and hyponatremia. Moreover, ongoing research offers hope for the development of more effective and individualized treatments, promising improved outcomes and a higher quality of life for those affected by these complex and challenging conditions. The continuous evolution of our understanding of cirrhosis and hyponatremia brings with it the potential for better care and, ultimately, a brighter future for those living with these conditions.

Acknowledgement

None.

Conflict of Interest

There are no conflicts of interest by author.

References

1. Angeli, Paolo, Florence Wong, Hugh Watson and Pere Gines, et al. “Hyponatremia in cirrhosis: Results of a patient population survey.”Hepatology44 (2006): 1535–1542.

   Google Scholar, Crossref, Indexed at

2. Gines, Pere, Tomas Berl, Mauro Bernardi and Daniel G. Bichet, et al. “Hyponatremia in cirrhosis: From pathogenesis to treatment.”Hepatology28 (1998): 851–864.

   Google Scholar, Crossref, Indexed at

3. Kim, W.Ray, Scott W. Biggins, Walter K. Kremers and Russell H. Wiesner, et al. “Hyponatremia and mortality among patients on the liver-transplant waiting list.”N Engl J Med359 (2008): 1018–1026.

   Google Scholar, Crossref, Indexed at

4. Cárdenas, Andres, Elsa Solà, Ezequiel Rodríguez and Rogelio Barreto, et al. “Hyponatremia influences the outcome of patients with acute-on-chronic liver failure: An analysis of the CANONIC study.”Crit Care18 (2014): 700.

   Google Scholar, Crossref, Indexed at

5. Costa, Dalila, Benedikt Simbrunner, Mathias Jachs and Lukas Hartl, et al. “Systemic inflammation increases across distinct stages of advanced chronic liver disease and correlates with decompensation and mortality.”J Hepatol74 (2021): 819–828.

   Google Scholar, Crossref, Indexed at

6. Wang, Ying-Wen, The-la Huo, Ying-Yang Yang and Ming-Chih Hou, et al. “Correlation and comparison of the model for end-stage liver disease, portal pressure, and serum sodium for outcome prediction in patients with liver cirrhosis.”J Clin Gastroenterol41 (2007): 706–712.

   Google Scholar, Crossref, Indexed at